Psychopharmacological Strategies in the Management of Posttraumatic Stress Disorder (PTSD): What Have We Learned?
Psychopharmacological Strategies in the Management of Posttraumatic Stress Disorder (PTSD): What Have We Learned?
复制标题
DOI：
10.1007/s11920-015-0564-2
复制
发表时间：
2015-04-01
影响因子：
6.7
通讯作者：
Friedman, Matthew J.
中科院分区：
文献类型：
--
作者：
Bernardy, Nancy C.;Friedman, Matthew J.
在过去的二十年中，创伤后应激障碍（PTSD）的药物治疗取得了重大进展。多中心随机临床试验（RCTs）已经注意到选择性5 - 羟色胺再摄取抑制剂（SSRIs）和5 - 羟色胺 - 去甲肾上腺素再摄取抑制剂（SNRIs）对PTSD治疗的疗效。不幸的是，在过去的10年中没有新的药物被批准用于治疗PTSD。尽管我们对PTSD的神经生物学的认识有了令人兴奋的新发现，但测试新药的临床试验却滞后了。这篇综述总结了基于PTSD独特病理生理学的近期研究，并提出了推动该领域前进的方法。
There have been significant advancements in the pharmacologic management of posttraumatic stress disorder (PTSD) in the past two decades. Multisite randomized clinical trials (RCTs) have noted the efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNR Is) for PTSD treatment. Unfortunately, there have been no new medications approved to treat PTSD in the past 10 years. Although there have been exciting new findings in our knowledge of the neurobiology of PTSD, clinical trials testing new medications have lagged. This review summarizes recent research that builds on the unique pathophysiology of PTSD and suggests ways to move the field forward.